Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 3, 2008, Pages

  Zhou, Yunfeng ^a   Zhang, Xiaoyan ^a   Chen, Lihong ^a   Wu, Jing ^a   Dang, Huaixin ^a   Wei, Mingfen ^a   Fan, Yanbo ^a   Zhang, Yahua ^b   Zhu, Yi ^a   Wang, Nanping ^a   Breyer, Matthew D ^b   Guan, Youfei ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lipid; Microarrays; Nephrotic syndrome

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; APOLIPOPROTEIN A1; CARBOXYLYASE; DICHLORISOPRENALINE; DIPHOSPHOMEVALONATE DECARBOXYLASE; GERANYLTRANSFERASE; LANOSTEROL SYNTHETASE; NADPH STEROID DEHYDROGENASE LIKE PROTEIN; OXIDOREDUCTASE; PUROMYCIN AMINONUCLEOSIDE; SQUALENE SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; SYNTHETASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; FATTY ACID; LIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ACC GENE; AGPAT 3 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DCI GENE; DGAT 1 GENE; DOWN REGULATION; ELOVL2 GENE; ELOVL6 GENE; FAS GENE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GPAM GENE; IMMUNOBLOTTING; LIPID METABOLISM; LIVER METABOLISM; MALE; MCAD GENE; NEPHROTIC SYNDROME; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; DNA MICROARRAY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CHOLESTEROL; FATTY ACIDS; GENE EXPRESSION PROFILING; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPIDS; LIVER; MALE; NEPHROTIC SYNDROME; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 54449087638     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00046.2008     Document Type: Article

References (50)

1. Abe I, Prestwich GD. Molecular cloning, characterization, and functional expression of rat oxidosqualene cyclase cDNA. Proc Natl Acad Sci USA 92: 9274-9278, 1995.
2. al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L. Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids 33: 165-169, 1998.
3. Antonenkov VD, Croes K, Waelkens E, Van Veldhoven PP, Mannaerts GP. Identification, purification and characterization of an acetoacetyl-CoA thiolase from rat liver peroxisomes. Eur J Biochem 267: 2981-2990, 2000.
4. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100: 391-398, 2000.
5. Caldas H, Herman GE. NSDHL, an enzyme involved in cholesterol biosynthesis, traffics through the Golgi and accumulates on ER membranes and on the surface of lipid droplets. Hum Mol Genet 12: 2981-2991, 2003.
6. Cinti DL, Cook L, Nagi MN, Suneja SK. The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog Lipid Res 31: 1-51, 1992.
7. Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 62: 245-259, 2004.
8. Ericsson J, Jackson SM, Kim JB, Spiegelman BM, Edwards PA. Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J Biol Chem 272: 7298-7305, 1997.
9. Genest J Jr, Marcil M, Denis M, Yu L. High density lipoproteins in health and in disease. J Invest Med 47: 31-42, 1999.
10. 3H-palmitate. Lipids 15: 108-112, 1980.
11. Glass CK, Pittman RC, Keller GA, Steinberg D. Tissue sites of degradation of apoprotein A-I in the rat. J Biol Chem 258: 7161-7167, 1983.
12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
13. Goldstein JL, Rawson RB, Brown MS. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch Biochem Biophys 397: 139-148, 2002.
14. Hiltunen JK, Qin Y. Beta-oxidation - strategies for the metabolism of a wide variety of acyl-CoA esters. Biochim Biophys Acta 1484: 117-128, 2000.
15. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131, 2002.
16. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100: 12027-12032, 2003.
17. Jackson SM, Ericsson J, Mantovani R, Edwards PA. Synergistic activation of transcription by nuclear factor Y and sterol regulatory element binding protein. J Lipid Res 39: 767-776, 1998.
18. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323: 579-584, 1990.
19. Kaysen GA, Hoye E, Jones H Jr. Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol Renal Fluid Electrolyte Physiol 268: F532-F540, 1995.
20. Kim CH, Kim HJ, Mitsuhashi M, Vaziri ND. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome. Metabolism 56: 1377-1382, 2007.
21. Kim KH. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr 17: 77-99, 1997.
22. Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51: 1761-1765, 1997.
23. Liang K, Vaziri ND. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56: 621-626, 1999.
24. Liang KH, Oveisi F, Vaziri ND. Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49: 855-860, 1996.
25. Marsh JB. Lipoprotein metabolism in experimental nephrosis. Proc Soc Exp Biol Med 213: 178-186, 1996.
26. Marsh JB, Drabkin DL. Metabolic channeling in experimental nephrosis. II. Lipide metabolism. J Biol Chem 212: 633-639, 1955.
27. Marshall JF, Apostolopoulos JJ, Brack CM, Howlett GJ. Regulation of apolipoprotein gene expression and plasma high-density lipoprotein composition in experimental nephrosis. Biochim Biophys Acta 1042: 271-279, 1990.
28. Matsuzaka T, Shimano H, Yahagi N, Yoshikawa T, Amemiya-Kudo M, Hasty AH, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Takahashi A, Yato S, Sone H, Ishibashi S, Yamada N. Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J Lipid Res 43: 911-920, 2002.
29. McKenzie TL, Jiang G, Straubhaar JR, Conrad DG, Shechter I. Molecular cloning, expression, and characterization of the cDNA for the rat hepatic squalene synthase. J Biol Chem 267: 21368-21374, 1992.
30. Michihara A, Sawamura M, Yamori Y, Akasaki K, Tsuji H. Difference in subcellular distribution between 45- and 37-kDa mevalonate pyrophosphate decarboxylase in rat liver. Biol Pharm Bull 24: 1347-1350, 2001.
31. Moon YA, Lee JJ, Park SW, Ahn YH, Kim KS. The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter. J Biol Chem 275: 30280-30286, 2000.
32. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22: 135-142, 1993.
33. Ramakrishna S, Benjamin WB. Fat cell protein phosphorylation. Identification of phosphoprotein-2 as ATP-citrate lyase. J Biol Chem 254: 9232-9236, 1979.
34. Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 61: 157-162, 2002.
35. Shafrir E, Brenner T. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rat in vivo. Lipids 14: 695-702, 1979.
36. Shearer GC, Couser WG, Kaysen GA. Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL. Kidney Int 65: 228-237, 2004.
37. Spady DK, Bilheimer DW, Dietschy JM. Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci USA 80: 3499-3503, 1983.
38. Spady DK, Turley SD, Dietschy JM. Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver. J Lipid Res 26: 465-472, 1985.
39. Sparks CE, Tennenberg SD, Marsh JB. Catabolism of the apolipoproteins of HDL in control and nephrotic rats. Biochim Biophys Acta 665: 8-12, 1981.
40. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89: 9252-9256, 1992.
41. Tarugi P, Calandra S, Chan L. Changes in apolipoprotein A-I mRNA level in the liver of rats with experimental nephrotic syndrome. Biochim Biophys Acta 868: 51-61, 1986.
42. Teruya JH, Kutsunai SY, Spear DH, Edwards PA, Clarke CF. Testis-specific transcription initiation sites of rat farnesyl pyrophosphate synthetase mRNA. Mol Cell Biol 10: 2315-2326, 1990.
43. Thabet MA, Challa A, Chan JC, Pandak WM, Heuman DM, Vlahcevic ZR. Studies of alteration of hepatic cholesterol metabolism in puromycin-induced nephrotic syndrome in rats. Kidney Int 44: 789-794, 1993.
44. Vaziri ND, Kim CH, Phan D, Kim S, Liang K. Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int 66: 262-267, 2004.
45. Vaziri ND, Liang KH. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-density lipoprotein receptor deficiencies in nephrotic syndrome. Circulation 110: 419-425, 2004.
46. Vaziri ND, Liang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50: 887-893, 1996.
47. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48: 1979-1985, 1995.
48. Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK. Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA. Hum Mol Genet 3: 531-537, 1994.
49. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 23: 331-346, 1994.
50. Zeng J, Li D. Intrinsic isomerase activity of medium-chain acyl-CoA dehydrogenase. Biochemistry 44: 6715-6722, 2005.